CMES202 GLP-1 Receptor Agonists: What’s Known? What’s New?

Program: CMES Ancillary Events
Saturday, June 15, 2013: 6:30 PM-9:30 PM
Yerba Buena Salon 7 (San Francisco Marriott Marquis)

Learning Objectives:

  • Improving glycemic control in early T2DM and potential for use earlier in disease progression (ie, prediabetes)
  • Improving glycemic control in combination with insulin in T2DM and potential for use in T1DM
  • Improving glycemic control in elderly patients and potential for use in pediatric patients
  • Current understanding of safety, focusing on cardiovascular safety and potential cardiovascular effects
  • Non-glycemic effects that may impact other therapeutic goals (eg, weight loss, decreased blood pressure, lipid effects)
This activity is supported by an educational grant from Novo Nordisk Inc
7:00 PM
Robert Edward Ratner, MD, American Diabetes Association, Bethesda, MD
7:15 PM
Vanita R Aroda, MD, MedStar Health Research Institute, Hyattsville, MD
7:35 PM
Paresh Dandona, MD, PHD, FRCP, FACP, Dept of Med, Fillmore Hosp/State Univ of NY, Buffalo, NY
7:55 PM
Laurie Baggio, PHD, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada
8:15 PM
Carol H Wysham, MD, University of Washington
8:35 PM
Robert Edward Ratner, MD, American Diabetes Association, Bethesda, MD, Vanita R Aroda, MD, MedStar Health Research Institute, Hyattsville, MD, Paresh Dandona, MD, PHD, FRCP, FACP, Dept of Med, Fillmore Hosp/State Univ of NY, Buffalo, NY, Laurie Baggio, PHD, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada and Carol H Wysham, MD, University of Washington
See more of: CMES Ancillary Events